Who can use Zydelig(Idelalisib)?

Mektovi (binimetinib) is a kinase inhibitor for treating certain cancers. Its price is influenced by multiple factors. 

Who can use Zydelig(Idelalisib)?

High R&D costs play a crucial role. Developing this drug, like other innovative medications, demands substantial investment in research, pre - clinical and clinical trials. For example, researching its efficacy against BRAF - mutated cancers involves complex studies and significant financial input.

Secondly, patent protection grants Amgen, the manufacturer, exclusive rights to sell it. Without generic competition during this period, they can set a relatively high price. Production costs also matter. Precise manufacturing processes and strict quality control for its formulation add to the overall expense.